Check out how Celsius token burn surprised the markets, rallying from $0.14 to $0.96 after the burn was finally noticed.

SCI’s Multikine has moved one more step closer to regulatory approval, as the company announced plans to run another Phase ...

Celsius Network's native token CEL saw a 370% rally in a week, defying market selloff. The token burn, breakout, and buying ...

CEL-SCI Corp (NASDAQ:CVM) shares are trading higher by 18.6% to $1.98 during Wednesday’s session after the company received ...

Listen to this article CEL-SCI Corporation, the Vienna, Virginia-based biotechnology company with operations in Baltimore, ...

Celsius Network has burned 94% of its CEL token supply, eliminating 652M tokens through a transaction from its own wallet.

The company’s primary candidate, trem-cel (VOR33), has shown promise in the treatment of Acute Myeloid Leukemia (AML), with the clinical trial expanding to include Myelodysplastic Syndrome (MDS) ...

SCI’s selection criteria defining the Multikine target population before surgery Selected patient population had 73% survival with Multikine vs. 45% without Multikine based on analysis of completed ...

Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma ...

Unlock lucrative opportunities as we unveil today's top crypto gainers – Celsius, UMA, Harmony, and Toncoin. Get actionable ...

On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic ...

Data from the study showed that exa-cel prevented vaso-occlusive crises in all but 1 of the 30 evaluable patients for at ...